Patent US12611427B2 - TIL Treatment for NSCLC Refractory to Anti-PD-1 Antibody - Iovance
Summary
The USPTO granted patent US12611427B2 to Iovance Biotherapeutics, Inc. on April 28, 2026, covering processes and methods for preparing tumor-infiltrating lymphocytes (TILs) with increased therapeutic efficacy for treating non-small cell lung carcinoma refractory to anti-PD-1 antibody treatment. The patent names inventors Maria Fardis and Arvind Natarajan and contains 12 claims across multiple CPC classifications including A61K, C07K, and C12N categories.
“The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody.”
About this source
Granted patents in USPTO classification C07K, covering peptides, proteins, antibodies, and related biological molecules. Around 160 grants a month, each with the patent number, title, applicant, inventor names, and full abstract. Unlike published applications (which reveal in-progress research), grants are enforceable rights and signal what a company can now litigate or license. Watch this if you run an antibody or protein biologics program, advise on patent portfolio strategy for biologics companies, scout for licensing opportunities on recently granted claims, or track which research institutions are converting their early peptide work into issued patents.
What changed
The USPTO issued patent US12611427B2 to Iovance Biotherapeutics, Inc., granting intellectual property protection for improved and shortened processes of preparing tumor-infiltrating lymphocytes for treating non-small cell lung carcinoma patients who are refractory to anti-PD-1 antibody treatment. The patent application was filed on November 4, 2019.
Affected parties including competing pharmaceutical and biotechnology companies developing cell-based cancer immunotherapies should be aware of this newly granted IP position. Companies pursuing similar TIL-based approaches for NSCLC or anti-PD-1 refractory cancers may need to evaluate potential infringement risks or explore licensing opportunities with Iovance Biotherapeutics.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Treatment of NSCLC patients refractory for anti-PD-1 antibody
Grant US12611427B2 Kind: B2 Apr 28, 2026
Assignee
Iovance Biotherapeutics, Inc.
Inventors
Maria Fardis, Arvind Natarajan
Abstract
The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody.
CPC Classifications
A61K 35/13 A61K 39/4611 A61K 39/4644 A61K 45/06 A61K 2239/38 A61K 2239/48 A61K 2239/55 A61K 31/675 A61K 31/7076 A61K 38/2013 A61K 35/17 A61K 31/519 C07K 16/2809 C07K 16/2818 C07K 16/2827 C12N 5/0635 C12N 5/0638 C12N 2501/2302 C12N 2501/515 A61P 35/00
Filing Date
2019-11-04
Application No.
17290710
Claims
12
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.